Dr. Bui is a Senior Member in the Department of Pathology and the Scientific Director of the Analytic Microscopy Core at the Moffitt Cancer Center in Tampa, FL. She is also a Professor and the Director of the Cytopathology Fellowship Program at the University of South Florida Morsani College of Medicine. Her expertise includes cancer diagnostics through surgical pathology, cytopathology, biomarker testing, digital pathology and AI. She has received patents in digital pathology and cancer diagnostics, and has published over 200 peer-reviewed articles, 30 book chapters and 3 books. Dr. Bui serves on committees organizing national meetings and has been frequently invited to speak nationally and internationally. She chaired the Expert Panel of the Quantitative Image Analysis (QIA) project and developed the guidelines to improve the accuracy, precision, and reproducibility of breast cancer HER2 IHC QIA interpretation and reporting of the College of American Pathologists (CAP). She is the editorial board member of multiple journals. She served as the President of the Chinese American Pathologists Association (2021-2022), the President of the Digital Pathology Association (2019), and the President of Medical Staff at Moffitt (2018-2020). She has chaired multiple committees of the CAP and currently chairs the Digital and Computational Pathology Committee. Dr. Bui has earned several national awards including the 2019 CAP Distinguished Patient Care Award.

Dr. Feldman’s professional interests revolve around the development, integration, and adoption of information technologies in the discipline of Pathology. One of his main areas of interest within this broad discipline is in the field of digital imaging. Alongside his team, he has been studying pathology imaging on several fronts including interactions between pathology/radiology (radiopathogenomics of prostate cancer and breast carcinoma), development and utilization of computer assisted diagnostic algorithms for machine vision in prostate and breast cancer. More recently they have been developing deep learning methods for complex interrogation of pathology slides both within the cancer domain as well as in cardiovascular and renal pathology. They have also been developing methods to apply multispectral imaging for the analysis of multiplexed immunohistochemistry and immunofluorescence to tissues along with the development of a quantitative system for scoring and analyzing these studies at a cytometric level on surgical pathology slides. The efforts have been recognized by the national funding agencies of the NIH and DOD as well as industry sponsored projects.

Dr. Hicks is Director of the IHC/ISH Laboratories and the Breast Pathology Subspeciality Service at the University of Rochester Medical Center. He has held faculty positions at Cleveland Clinic Foundation, Roswell Park Cancer Institute, and the University of Rochester Medical Center. His current research interests focus on the molecular genetic profiling of clinical samples from patients with cancer. Much of his recent work has involved a search for new molecular genetic markers to help better understand the prognosis and guide therapeutic management of breast cancer.

Dr. Jaffer is Professor of Pathology, Molecular and Cell Based Medicine, at The Icahn School of Medicine at Mount Sinai. She received her medical degree from Icahn School of Medicine at Mount Sinai, followed by residency at Mount Sinai in Anatomic and Clinical Pathology and then oncologic Surgical Pathology and Cytopathology fellowship, both at Memorial Sloan Kettering. She is board certified in Anatomic and Clinical Pathology as well as Cytopathology and has been in practice for more than 20 years. She is currently the system wide Director of Breast Pathology at Mount Sinai Hospital. Dr. Jaffer continues to author publications related to breast pathology and gives short courses at USCAP.

Dr. Khoury has been working as the Chief of Breast Pathology service at Roswell Park Comprehensive Cancer Center (RPCCC), Buffalo NY since 2019, and vice chair of anatomic pathology since 2021. He was promoted to full professor in 2016 in RPCCC, and in 2017 in University of Buffalo. He has developed expertise in breast pathology through training along with extensive research projects in the field. Although his research focus is breast related diseases, he doesn’t have a specific area of interest, and his research has been conducted to answer clinical questions faced during regular sign out. An area pertinent to his role includes issues related to HER2 testing and evaluation, including but not limited to pre-analytical effects of delay to formalin fixation (cold ischemic time); molecular analysis of HER2 gene; maximizing concordance between IHC and FISH; the role of tumor infiltrating lymphocytes in the clinical outcome; and the epidemiology of various types of breast cancers including racial disparity.

Dr. Krishnamurthy is a Professor of Pathology at The University of Texas MD Anderson Cancer Center in Houston, TX. Her areas of expertise include breast pathology and cytopathology. She is the pathology core leader of the Morgan Welch Inflammatory Breast Cancer research and clinic at MD Anderson Cancer Center. Dr. Krishnamurthy has contributed significantly towards patient care, education, and clinical translational research, and has also been a principal investigator and co-investigator in several clinical trials related to breast cancer. Dr. Krishnamurthy’s current research interest includes molecular and proteomic profiling of intraductal and invasive carcinoma to identify potential biomarkers of clinical significance in the management of breast cancer. In addition, she is also an avid investigator of tissue imaging and artificial intelligence pertaining to applications of digital pathology.

Dr. Tozbikian is an Anatomic and Clinical Pathology board-certified Surgical Pathologist with a specialization in Breast Pathology. His research is focused on diagnostic, predictive, and therapeutic biomarkers for use in breast cancer, as well as the practical application of advanced digital imaging technology in breast pathology. Dr. Tozbikian joined the Department of Pathology at The Ohio State University Wexner Medical Center in 2013. He is an Associate Professor and Breast Pathology Division Director and serves as a subspecialty pathologist on the Breast and Genitourinary Pathology services.

Dr. Wei is Professor with Tenure and the Barbara F. Atkinson Endowed Professor, Director of Translational Research at the Department of Pathology and Laboratory Medicine, University of Kansas Medical Center. His major research interests include discovery and evaluation of biomarkers in breast cancer and other malignancies, evaluation of prognostic factors in breast cancer and malignant bone tumors, and tumor bone metastasis. Dr. Wei has published over 300 professional writings in these fields, including more than 160 manuscripts in some of the leading peer-reviewed journals such as JAMA, Journal of Clinical Investigation, and Modern Pathology. He has edited 3 textbooks and contributed 8 monographs in the fields of breast pathology and bone/soft tissue pathology, recognizing his expertise in these areas. Dr. Wei is the Editor-in-Chief of Human Pathology Reports and editorial board member of several key pathology journals.

Dr. Wen is Director of the Breast Pathology Fellowship at Memorial Sloan Kettering Cancer Center in New York. She is a board-certified pathologist with a specialization in breast pathology. She has authored over 100 peer-reviewed publications, contributed book chapters in the WHO Classification of Tumors of the Breast 5th Edition (2019), and in Rosen’s Breast Pathology 5th Edition (2020). She is also the Director of Education and Treasurer of the International Society of Breast Pathology (ISBP).